My Cart

IL-5 R alpha

IL-5 R alpha Overview

English NameInterleukin-5 receptor subunit alphaApproved Drugs1
Drugs in Clinical Trials2Target SynonymInterleukin 5 Receptor, Alpha,Interleukin-5 Receptor Subunit Alpha,HSIL5R3,Interleukin-5 Receptor Alpha Chain,CDw125,Interleukin-5 Receptor alpha Subunit,Interleukin 5 Receptor Type 3,CD125 Antigen,Interleukin 5 Receptor Subunit Alpha,IL-5 Receptor Subunit Alpha,IL-5R-Alpha,IL5R,IL5RA,CD125,IL-5RA,IL-5R Subunit Alpha
Highest Development StageApproved
English NameInterleukin-5 receptor subunit alpha
Target SynonymInterleukin 5 Receptor, Alpha,Interleukin-5 Receptor Subunit Alpha,HSIL5R3,Interleukin-5 Receptor Alpha Chain,CDw125,Interleukin-5 Receptor alpha Subunit,Interleukin 5 Receptor Type 3,CD125 Antigen,Interleukin 5 Receptor Subunit Alpha,IL-5 Receptor Subunit Alpha,IL-5R-Alpha,IL5R,IL5RA,CD125,IL-5RA,IL-5R Subunit Alpha
Approved Drugs1
Drugs in Clinical Trials2
Highest Development StageApproved

IL-5 R alpha Product List

  • Product Category

    Protein (4)

  • Product Status

    Launched (4)

  • Species

    Human (3)Mouse (1)

  • Tag

    His Tag (2)Fc Tag (1)Avi Tag & Fc Tag (1)

  • Conjugate

    Unconjugated (3)Biotin-labeled (1)

IL-5 R alpha Background

Interleukin-5 receptor subunit alpha (IL5RA) is also known as IL-5 receptor subunit alpha, IL-5R subunit alpha and CD125,which is a single-pass type I membrane protein that belongs to the type I cytokine receptor family and type 5 subfamily.IL5R, a heterodimer of an alpha and a beta subunit, is expressed on eosinophils and basophils. IL5RA / CD125 is the receptor for interleukin-5 (IL5) and the alpha chain can bind to IL5. The WSXWS motif of IL5RA appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding.The beta subunit of IL5R is common to the IL3, IL5 and GM-CSF receptors.

IL-5 R alpha Synonyms

IL5Ra,CD125

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
IL-5 CAR-T Cell Therapy (Zhejiang University)Phase 1 ClinicalZhejiang UniversityHematologic Diseases; Neoplasms
Details
TrabikibartCSL-311Phase 1 ClinicalCsl LtdAsthma
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
BenralizumabKHK-4563; MEDI-563; BIW-8405; BIW-8405-IL-5RApprovedBiowa Inc, Medimmune LlcFasenra, 凡舒卓United StatesAsthmaAstrazeneca Ab2017-11-14Asthma; Asthma, Exercise-Induced; Bronchiectasis; Chronic Urticaria; Dermatitis; Dermatitis, Atopic; Drug Hypersensitivity Syndrome; Eczema; Eosinophilia; Eosinophilic Asthma; Eosinophilic Esophagitis; Eosinophilic gastroenteritis (EG); Eosinophilic Granulomatosis With Polyangiitis; Gastroenteritis; Genetic Diseases, Inborn; Granulomatosis with Polyangiitis; Hematologic Diseases; Hypereosinophilic Syndrome; Hypersensitivity; Hypersensitivity, Immediate; Immune System Diseases; Leukocyte Disorders; Nasal Polyps; Pemphigoid, Bullous; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Diseases; Sinusitis; Skin Diseases; Skin Diseases, Eczematous; Skin Diseases, Genetic
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information